SCHEMBL16894151

SCHEMBL16894151

CC(C)N(CC(=O)O)S(=O)(=O)c1ccc(Cl)nc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.60
MAPT P10636 1/20 0.55
ALDH1A1 P00352 6/20 0.51
MEN1 O00255 2/20 0.51
KMT2A Q03164 2/20 0.51
TDP1 Q9NUW8 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
MMP1 P03956 2/20 0.43
MMP2 P08253 2/20 0.43
MMP9 P14780 2/20 0.43
MMP8 P22894 2/20 0.43
MMP14 P50281 2/20 0.43
DAGLA Q9Y4D2 2/20 0.42
POLB P06746 1/20 0.41
PKM P14618 1/20 0.41
MMP3 P08254 1/20 0.40
MMP13 P45452 1/20 0.40
MMP16 P51512 1/20 0.40
ADAM17 P78536 1/20 0.40
GAA P10253 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5297763 0.76 MMP2 (0.57) MAPTKMT2AMMP1MMP2MMP9
SCHEMBL26931067 0.75 ALDH1A1 (0.61) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL15719242 0.75 KEAP1 (0.54) KMT2AMMP1MMP2MMP9MMP8
SCHEMBL2567557 0.75 MAPT (0.48) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL14275127 0.72 SMN1; SMN2 (0.74) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL671244 0.72 SMN1; SMN2 (0.69) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL17645850 0.71 MAPT (1.00) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL9880045 0.70 SMN1; SMN2 (0.53) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL12077838 0.70 MAPT (0.73) SMN1; SMN2MAPTALDH1A1MEN1KMT2A
SCHEMBL6153032 0.69 MAPT (0.58) SMN1; SMN2MAPTALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2900642-B1 SUBSTITUTED SULFONAMIDE COMPOUNDS HOFFMANN LA ROCHE (CH) 2018-02-28 EP disclosed
US-9580411-B2 Substituted sulfonamide compounds HOFFMANN-LA ROCHE INC. (US) 2017-02-28 US disclosed
EP-2900642-A1 SUBSTITUTED SULFONAMIDE COMPOUNDS F. Hoffmann-La Roche AG (CH) 2015-08-05 EP disclosed
US-20150197509-A1 SUBSTITUTED SULFONAMIDE SOLUTIONS GENENTECH, INC. (US) 2015-07-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150197509-A1 SUBSTITUTED SULFONAMIDE SOLUTIONS TRPA1, TRPV1, TRPV5 SMN1; SMN2 828/4885MAPT 3336/4885ALDH1A1 949/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.